VYEPTI dosing and administration overview1,2

VYEPTI IV infusion bag icon

Withdraw 1 mL of VYEPTI from a single-dose vial and inject it into a 100 mL bag of 0.9% Sodium Chloride Injection, USP. No other diluents may be used.*

Room temperature icon

Use an IV infusion set with a 0.2 μm or 0.22 μm in-line or add-on sterile filter. Always infuse at room temperature.

Infuse over 30 minutes icon

Infuse over approximately 30 minutes. After infusion is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP.

VYEPTI 100 mg is the recommended dose. Some patients may benefit from the available and approved 300 mg dose. For more information on the 300 mg data, please see the Prescribing Information.

*Please see dilution instructions below for preparing and administering the 300 mg dose.

IV, intravenous.

VYEPTI Dosing and Administration Video

Step-by-step instructions for the preparation and administration of VYEPTI.

VYEPTI Dosing and Administration Video

Dosing and administration details

VYEPTI infusion administration supplies and VYEPTI vial

Pre-infusion1,2

List of supplies per infusion

  • Sterile needle and syringe
    An 18- to 24-gauge needle was used in clinical trials
  • 100 mL bag of 0.9% Sodium Chloride Injection, USP
    The infusion bags must be made of polyvinyl chloride, polyethylene, or polyolefin
  • IV infusion set with a 0.2 μm or 0.22 μm in-line or add-on sterile filter
  • Additional 20 mL of 0.9% Sodium Chloride Injection, USP
VYEPTI vial and syringe

Dilution instructions

VYEPTI requires dilution prior to administration. Use appropriate aseptic technique when preparing VYEPTI solution for intravenous (IV) infusion.

  1. VYEPTI 100 mg dose: Withdraw 1 mL of VYEPTI from a single-dose vial using a sterile needle and syringe. Inject the 1 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP. No other diluents may be used. VYEPTI 300 mg dose: Withdraw 1 mL of VYEPTI from each of 3 single-dose vials using a sterile needle and syringe. Inject the resulting 3 mL content into a 100 mL bag of 0.9% Sodium Chloride Injection, USP. No other diluents may be used.
  2. Gently invert the VYEPTI solution to mix completely. Do not shake.
  3. Following dilution, VYEPTI solution must be infused within 8 hours. During this time, the VYEPTI solution should be stored at room temperature, 20°C to 25°C (68°F to 77°F). Do not freeze.

VYEPTI single-dose vials contain no preservative; discard unused portion remaining in the vial.

IV tubing

Infusion administration instructions1,2

3 quick steps to administer VYEPTI 

  1. Administer the diluted VYEPTI solution by IV. Use an IV infusion set with a 0.2 μm or 0.22 μm in-line or add-on sterile filter. Always infuse at room temperature.
  2. Infuse over approximately 30 minutes.
  3. After administration is complete, flush the line with 20 mL of 0.9% Sodium Chloride Injection, USP.

General considerations1

  • VYEPTI is a clear to slightly opalescent, colorless to brownish-yellow solution 
  • Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration 
  • Do not use if the liquid contains visible particulate matter or is cloudy or discolored 
  • Do not administer VYEPTI as an IV push or bolus injection 
  • No other medications should be administered through the infusion set or mixed with VYEPTI

Schedule appointments with your patients once every 3 months (12 weeks).

VYEPTI carton and vial

Storing VYEPTI1

  • Store refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light until time of use
  • Do not freeze or shake
  • The expiration date of each VYEPTI single-dose vial can be found on the label

For questions about storage and stability, please contact Lundbeck Medical Information by phone at 833-4-VYEPTI, by email, or by submitting a medical information request through your local account manager.

No loading dose is required for VYEPTI.

One 30-minute IV infusion every 3 months1

VYEPTI CONNECT Enrollment Form

Get your patients started with VYEPTI

Download and fill out the VYEPTI CONNECT Enrollment Form to initiate a benefits investigation on behalf of your patient. 

You may also be interested in:

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

References:
  1. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
  2. Data on file. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.